Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | August 2011 |
| End Date: | August 2017 |
Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer
This study is a phase 1/2a, open label, dose escalation and safety study of APC-100
(2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.
(2,2,5,7,8-Pentamethyl-6-chromanol) in men with advanced prostate cancer.
Inclusion Criteria:
- Patients with histopathologically proven adenocarcinoma of the prostate
- Patients must have progressive disease
- Patients must have had prior treatment with bilateral orchiectomy or androgen
deprivation therapy with an LHRH-blocker with evidence of treatment failure
Exclusion Criteria:
- Patients treated with other secondary hormonal therapies
- Patients with prior chemotherapy given for castrate-resistant prostate cancer
- Patients with prior radiation therapy completed less than 4 weeks prior enrollment
- Patients with prior investigational therapies within 4 weeks before treatment with
APC-100
- Evidence of active second malignancy
We found this trial at
2
sites
600 Highland Ave.
Madison, Wisconsin 53792
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Carbone Cancer Center UW Carbone Cancer Center holds the unique distinction of...
Click here to add this to my saved trials
Click here to add this to my saved trials